SCHEMBL676277

SCHEMBL676277

CC(N)CCCc1ccc2c(n1)[nH]c1ccc(C=Cc3ccccc3)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 3/20 0.37
HTR2A P28223 3/20 0.33
ALK Q9UM73 3/20 0.33
CA5A P35218 1/20 0.32
MAPKAPK2 P49137 1/20 0.32
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
IP6K3 Q96PC2 1/20 0.31
IP6K2 Q9UHH9 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31
GABRA1 P14867 1/20 0.31
IDO1 P14902 1/20 0.31
GABRB1 P18505 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675011 0.89 ALK (0.37) ALKTP53POLBMAPTSMN1; SMN2
SCHEMBL676564 0.85 IP6K1 (0.37) IP6K1ALKCA5AMAPKAPK2IP6K3
SCHEMBL3725587 0.85 GABRP (0.40) IP6K1ALKMAPKAPK2TP53MAPT
SCHEMBL3725585 0.85 GABRP (0.40) IP6K1ALKMAPKAPK2TP53MAPT
SCHEMBL675733 0.84 JAK2 (0.36) ALKCA5AGABRPGABRDGABRA1
SCHEMBL675098 0.84 IP6K1 (0.36) IP6K1ALKCA5AMAPKAPK2IP6K3
SCHEMBL675100 0.81 IP6K1 (0.37) IP6K1ALKCA5AMAPKAPK2TP53
SCHEMBL675097 0.77 IP6K1 (0.37) IP6K1ALKCA5AMAPKAPK2TP53
SCHEMBL677071 0.76 GABRA1 (0.39) ALKGABRA1GABRG2GABRB3GABRA5
SCHEMBL677055 0.76 ALK (0.37) ALKESR1TP53MAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 IP6K1 3330/4885HTR2A 4375/4885ALK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.